Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics Inc.

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Neuronetics, with a price target of $3.00. Maeder covers the ...

Neuronetics (STIM) Receives a Buy from Piper Sandler

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HeartFlow, Inc. (HTFL), Neuronetics (STIM) and 4D Mo...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Neuronetics ( ($STIM) ) has provided an update. On March 12, 2026, Neuronetics’ board appointed veteran medtech executive Daniel L. Reuvers as pres...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STIM	$1.58	0.00%	3.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	STIM	$1.58	0%	3.59M
3
4
5
6

STIM

STIM

Latest News for STIM

Get Neuronetics Inc. Data in Excel

Get Neuronetics Inc. Data in Excel